RNA

Atrium Therapeutics, Inc. Common Stock

RNA

Market cap $204M

13.13 USD

+0.44

3.47%

At close Updated Mar 20, 4:00 PM EDT

Pre-market

After hours

12.98

-0.15

1.14%

1 day

3.47%

5 days

-4.65%

1 month

-10.98%

3 months

-10.98%

6 months

-10.98%

Year to date

-10.98%

1 year

-10.98%

5 years

-10.98%

10 years

-10.98%

About: Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.

Employees: 391

Healthcare Biotechnology

–

Funds holding %

of 8,088 funds

Explore Fund Trends

Analysts bullish %

of 1 analysts

See Analyst Outlook

–

Positive news %

of articles